Sign Up Today and Learn More About CoreMedic GmbH Stock

Invest in or calculate the value of your shares in CoreMedic GmbH or other pre-IPO companies through EquityZen's platform.

Get Started

CoreMedic GmbH Stock

CoreMedic develops and manufactures devices to address the treatment of heart valve diseases. Lead product: ChordArt TMVr - System

About CoreMedic GmbH Stock

Founded

2012

CoreMedic was initiated in 2012 as a spin-out of the Heart Center of University of Bern, Switzerland, in order to develop an innovative treatment concept for mitral valve regurgitation (MR). The initiators of CoreMedic had a simple but challenging idea: to combine the least invasive treatment option for MR, replacement of mitral chords, and the least invasive operational procedure into one new system: ChordArt. In 2017, the development of ChordArt had progressed towards first use in a human trial, enabling CoreMedic to attract institutional financing. The company moved to RIZ-innovation center at Radolfzell, Germany, located at Lake Constance close to the Swiss border within the leading medical technology cluster of Tuttlingen, Germany. Following successful conclusion of the first human trial of ChordArt in 2018, and two-year data confirming the powerful treatment effect of the ChordArt implant in patients with severe MR, CoreMedic GmbH is tirelessly working to make the ChordArt TMVr system available to patients. ​

CoreMedic GmbH Press Mentions

Stay in the know about the latest news on CoreMedic GmbH

CoreMedic GmbH Management

Leadership team at CoreMedic GmbH

CEO

Thomas Bauer

CFO

Rainer Hoegg

Locked Features

Join now and verify your accreditation status to gain access to:

  • CoreMedic GmbH current valuation
  • CoreMedic GmbH stock price
  • Available deals in CoreMedic GmbH and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in CoreMedic GmbH stock?

Accredited investors can buy pre-IPO stock in companies like CoreMedic GmbH through EquityZen funds. These investments are made available by existing CoreMedic GmbH shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell CoreMedic GmbH stock?

Shareholders can sell their CoreMedic GmbH stock through EquityZen's private company marketplace. EquityZen's network includes over 310K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 41K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."